All Stories

  1. International Union of Basic and Clinical Pharmacology. XXXX. Apelin Receptor Pharmacology in the Human Cardiovascular System and Emerging Clinical Applications.
  2. Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system
  3. The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
  4. The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets
  5. Bile acid receptor in GtoPdb v.2025.3
  6. Chemerin receptors in GtoPdb v.2025.3
  7. Ghrelin receptor in GtoPdb v.2025.3
  8. Succinate receptor in GtoPdb v.2025.3
  9. Trace amine receptor in GtoPdb v.2025.3
  10. Apelin receptor in GtoPdb v.2025.3
  11. Endothelin receptors in GtoPdb v.2025.3
  12. Short communications: Endothelin-1 in cardiac allograft vasculopathy
  13. Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study
  14. Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein
  15. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
  16. Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue
  17. Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor
  18. Targeting the apelin system for the treatment of cardiovascular diseases
  19. Current and future strategies for targeting the endothelin pathway in cardiovascular disease
  20. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  21. Urotensin receptor in GtoPdb v.2023.1
  22. Trace amine receptor in GtoPdb v.2023.1
  23. Thyrotropin-releasing hormone receptors in GtoPdb v.2023.1
  24. Class A Orphans in GtoPdb v.2023.1
  25. Motilin receptor in GtoPdb v.2023.1
  26. Neuropeptide W/neuropeptide B receptors in GtoPdb v.2023.1
  27. Endothelin receptors in GtoPdb v.2023.1
  28. Kisspeptin receptor in GtoPdb v.2023.1
  29. Succinate receptor in GtoPdb v.2023.1
  30. Apelin receptor in GtoPdb v.2023.1
  31. Bile acid receptor in GtoPdb v.2023.1
  32. QRFP receptor in GtoPdb v.2023.1
  33. Ghrelin receptor in GtoPdb v.2023.1
  34. Chemerin receptors in GtoPdb v.2023.1
  35. Oxoglutarate receptor in GtoPdb v.2023.1
  36. Class A Orphans in GtoPdb v.2022.3
  37. Trans-myocardial Extraction of Endothelin-1 Correlates with Increased Microcirculatory Resistance following Percutaneous Coronary Intervention
  38. In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA
  39. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
  40. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  41. Class A Orphans in GtoPdb v.2021.3
  42. Urotensin receptor in GtoPdb v.2021.3
  43. Succinate receptor in GtoPdb v.2021.3
  44. Ghrelin receptor in GtoPdb v.2021.3
  45. Chemerin receptors in GtoPdb v.2021.3
  46. The therapeutic potential of apelin in kidney disease
  47. Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
  48. Motilin receptor in GtoPdb v.2021.2
  49. Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
  50. Class A Orphans (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database
  51. Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  52. Kisspeptin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database
  53. Genes Encoding ACE2, TMPRSS2 and Related Proteins Mediating SARS-CoV-2 Viral Entry are Upregulated with Age in Human Cardiomyocytes
  54. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
  55. Advances in therapeutic peptides targeting G protein-coupled receptors
  56. Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  57. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  58. Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor
  59. QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  60. Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  61. Bile acid receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  62. Apelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  63. Oxoglutarate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  64. Chemerin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  65. Ghrelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  66. Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  67. Kisspeptin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  68. Motilin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  69. Neuropeptide W/neuropeptide B receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  70. Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  71. Thyrotropin-releasing hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  72. Trace amine receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  73. Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  74. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand
  75. International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function
  76. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  77. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  78. Pharmacological targeting of apelin impairs glioblastoma growth
  79. Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [ 18 F]FDG PET Imaging
  80. Vascular Imaging With 18 F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
  81. 18 F-Fluoride and 18 F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic StrokeCLINICAL PERSPECTIVE
  82. [Pyr1]Apelin-13(1–12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13
  83. Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial HypertensionClinical Perspective
  84. OUP accepted manuscript
  85. Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal RemodelingNovelty and Significance
  86. Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature
  87. Cardiac action of the first G protein biased small molecule apelin agonist
  88. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension
  89. The endothelin hormones, structure and function
  90. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells
  91. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  92. The Concise Guide to PHARMACOLOGY 2015/16: Overview
  93. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  94. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system
  95. Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography
  96. LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal
  97. Endothelin Receptors and Their Antagonists
  98. Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist
  99. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12
  100. Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis
  101. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
  102. In Vivo Mapping of Vascular Inflammation Using the Translocator Protein Tracer 18 F-FEDAA1106
  103. Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta
  104. The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro
  105. The Concise Guide to PHARMACOLOGY 2013/14: Overview
  106. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  107. Evolving pharmacology of orphan GPCRs: IUPHAR Commentary
  108. No evidence for a local renin-angiotensin system in liver mitochondria
  109. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension
  110. Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein–Coupled Receptors
  111. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
  112. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer
  113. Themed section: endothelin
  114. IUPHAR-DB: updated database content and new features
  115. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
  116. Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice
  117. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways
  118. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues
  119. The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
  120. GuideToPharmacology.org - an update
  121. Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy
  122. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  123. How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data
  124. Quantitative Phosphor Imaging Autoradiography of Radioligands for Positron Emission Tomography
  125. Radioligand Binding Assays and Their Analysis
  126. Receptor Binding Techniques
  127. Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor
  128. Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature
  129. Discovery of a Competitive Apelin Receptor (APJ) Antagonist
  130. Chemokine receptor CCR5: from AIDS to atherosclerosis
  131. Pharmacology of Renal Endothelin Receptors
  132. International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function
  133. Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation
  134. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
  135. Endothelial cell-specific ETBreceptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years o...
  136. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis
  137. Introduction
  138. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man
  139. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver
  140. EDITORIAL
  141. The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses
  142. FDG–PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis
  143. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S
  144. [Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
  145. International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature
  146. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation
  147. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system
  148. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo
  149. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system
  150. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
  151. Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[18F]fluorobenzoate and application to 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography
  152. Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration
  153. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function
  154. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease
  155. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106
  156. Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels
  157. Endothelin Receptors
  158. Urotensin-II Receptor
  159. ET-B Endothelin Receptor
  160. ET-A Endothelin Receptor
  161. Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation
  162. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis
  163. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system
  164. Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
  165. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt
  166. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man
  167. International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function
  168. Triptan-induced contractile (5-HT1Breceptor) responses in human cerebral and coronary arteries: relationship to clinical effect
  169. Emerging roles of apelin in biology and medicine
  170. Regulation of vascular reactivity by established and emerging GPCRs
  171. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List
  172. Receptor Binding Techniques
  173. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells
  174. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels
  175. Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera
  176. Down-regulation of ETA Receptors in ETB Receptor-deficient Mice
  177. Endothelin Receptor Pharmacology and Function in the Mouse: Comparison with Rat and Man
  178. In Vivo Imaging of Cardiovascular Endothelin Receptors Using the Novel Radiolabelled Antagonist [18F]-SB209670 and Positron Emission Tomography (microPET)
  179. CRF2receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators
  180. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries
  181. Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats
  182. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry
  183. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells
  184. Maternal Dexamethasone Increases Endothelin-1 Sensitivity and Endothelin A Receptor Expression in Ovine Foetal Placental Arteries
  185. Peptide and trace amine orphan receptors: prospects for new therapeutic targets
  186. Translating the human genome: renaissance of cardiovascular receptor pharmacology
  187. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system
  188. Life before birth: effects of cortisol on future cardiovascular and metabolic function*
  189. Is urotensin-II the new endothelin?
  190. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1
  191. Peptide Research Protocols
  192. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature
  193. Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography
  194. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
  195. Of mice and men: advances in endothelin research and first antagonist gains FDA approval
  196. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors
  197. Radioligand binding reveals chymase as the predominant enzyme for mediating tissue conversion of angiotensin I in the normal human heart
  198. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1receptor antagonist losartan
  199. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteriesin vitro
  200. [125I-His9]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis
  201. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery
  202. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats
  203. The endothelin system in human saphenous vein graft disease
  204. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
  205. Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system
  206. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1
  207. Endothelin receptor antagonism in patients with chronic heart failure
  208. Urotensin II: fish neuropeptide catches orphan receptor
  209. Preface
  210. Cellular Expression of Isoforms of Endothelin-Converting Enzyme-1 (ECE-1c, ECE-1b and ECE-1a) and Endothelin-Converting Enzyme-2
  211. Changes in ETA-, AT1- and AT2-Receptors in the Phenotypically Transformed Intimal Smooth Muscle Layer of Human Atherosclerotic Coronary Arteries
  212. Endothelin-A-Receptors in Human Aorta and Pulmonary Arteries are Downregulated in Patients With Cardiovascular Disease
  213. Expression and Characterization of the Human Endothelin-A-Receptor in Pichia pastoris
  214. No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease
  215. Novel Nitric Oxide Donors Reverse Endothelin-1-Mediated Constriction in Human Blood Vessels
  216. Syntheses of the First Endothelin-A- and -B-Selective Radioligands for Positron Emission Tomography
  217. Tissue-Specific Modulation of Endothelin Receptors in a Rat Model of Hypertension
  218. Evidence for Intracellular Endothelin-Converting Enzyme-2 Expression in Cultured Human Vascular Endothelial Cells
  219. Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain   Editorial Comment
  220. Endothelin receptor expression and pharmacology in human saphenous vein graft
  221. Secretory pathways in endothelin synthesis
  222. The therapeutic potential of PD156707 and related butenolide endothelin antagonists
  223. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review
  224. Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707
  225. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease
  226. Human Endothelial Cell Storage Granules : A Novel Intracellular Site for Isoforms of the Endothelin-Converting Enzyme
  227. Endothelin receptor subtypes and their functional relevance in human small coronary arteries
  228. Evidence Using Immunoelectron Microscopy for Regulated and Constitutive Pathways in the Transport and Release of Endothelin
  229. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney
  230. Characterization of [125I]-PD164333, an ETAselective non-peptide radiolabelled antagonist, in normal and diseased human tissues
  231. Characterization of Site-Directed Antisera Against Endothelin-Converting Enzymes
  232. Endothelin Peptide and Converting Enzymes in Human Endothelium
  233. Endothelin-Converting Enzyme in the Human Vasculature: Evidence for Differential Conversion of Big Endothelin-3 by Endothelial and Smooth-Muscle Cells
  234. PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts
  235. Relative Contribution of Endothelin A and Endothelin B Receptors to Vasoconstriction in Small Arteries from Human Heart and Brain
  236. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle
  237. Detection of Endothelin Receptors in Human Coronary Artery Vascular Smooth Muscle Cells But Not Endothelial Cells by Using Electron Microscope Autoradiography
  238. Differential distribution of endothelin receptor subtypes in placentae from normal and growth-restricted pregnancies
  239. Differential distribution of endothelin peptides and receptors in human adrenal gland
  240. Characterization of the binding of endothelin ETB selective ligands in human and rat heart
  241. Endothelin Peptide and Receptors in Human Atherosclerotic Coronary Artery and Aorta
  242. Selective downregulation of ETA receptor mRNA in renal transplant recipients on cyclosporin A revealed by quantitative RT-PCR
  243. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
  244. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments
  245. The endothelin system in the kidney
  246. Endothelin receptors in human coronary artery and aorta
  247. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
  248. Localization of endothelin peptides in human kidney
  249. Endocrinology and paracrinology
  250. Radioligand Binding Assays: Theory and Practice
  251. Expression of Endothelin Peptides and Mrna in the Human Heart
  252. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells
  253. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm
  254. Endothelin expression in the uterus
  255. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro
  256. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type
  257. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242
  258. Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells
  259. Selectivity of [125I]-PD 151242 for human, rat and porcine endothelin ETA receptors in the heart
  260. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature
  261. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro
  262. Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction
  263. Effects of Phosphoramidon and Pepstatin a on the Secretion of Endothelin-I and Big Endothelin-I by Human Umbilical Vein Endothelial Cells: Measurement by Two-Site Enzyme-Linked Immunosorbent Assays
  264. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats
  265. Davenport and Maguire reply
  266. Validation of mRNA Quantification in Human Kidney by a Novel Fluorescent Nested RT-PCR Method
  267. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?
  268. [125I]-PD 151242: a selective radioligand for human ETA receptors
  269. Isolation of Human Cardiac Endothelin Receptors by a Peptide-Receptor Mobility Shift Assay
  270. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney
  271. Alternatively Spliced mRNAs for Human Endothelin-2 and Their Tissue Distribution
  272. Endothelin: progress in pharmacology and physiology
  273. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium
  274. Characterisation of Immunoreactive Endothelin in Human kidney by RP-HPLC and RIA
  275. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
  276. Quantitative autoradiography reveals higher densities of specific calcitonin-gene-related peptide receptors in small intramyocardial compared with large epicardial coronary arteries
  277. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle.
  278. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle
  279. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart
  280. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue
  281. Localization of immunoreactive endothelin and proendothelin in the human lung
  282. Endothelin-like immunoreactivity in human endometrium
  283. Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b
  284. Endothelins in reproduction
  285. Localization and endogenous concentration of endothelin-like immunoreactivity in human placenta
  286. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues
  287. Binding sites for125I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells
  288. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography
  289. Mitogenic Effects of Vasoactive Peptides on Rat Vascular Smooth Muscle Cells
  290. Endothelin-1 stimulates prostaglandin F2α release from human endometrium
  291. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
  292. Atrial natriuretic factor mRNA and binding sites in the adrenal gland
  293. Localisation off binding sites for iodinated endothelin and saraffotoxin peptides in mammalian tissues using quantitative receptor autoradiography
  294. Endothelin-1 mRNA is widely expressed in porcine and human tissues.
  295. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects
  296. Binding Sites for125I-Labelled Endothelin-1 in the Kidneys: Differential Distribution in Rat, Pig and Man Demonstrated by Using Quantitative Autoradiography
  297. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway—II. Differential localization of dopamine and cholecystokinin receptors
  298. Comparison between brain paste and polymer [125I]standards for quantitative receptor autoradiography
  299. Effect of the formamidine insecticide chordimeform on feeding and reproduction in the noctuid moth, Spodoptera littoralis (Boisduval)
  300. Quantitative receptor autoradiography
  301. Sex-related differences in the concentration of Met-enkephalin-like immunoreactivity in the nervous system of an insect,Schistocerca gregaria, revealed by radioimmunoassay
  302. Octopamine distribution in the larvae and adults of two species of moth, Spodoptera littoralis and Manduca sexta
  303. The action of formamidines on octopamine receptors in the locust
  304. Toxicity of chlordimeform and amitraz to the egyptian cotton leafworm (Spodoptera littoralis) and the tobacco budworm (Heliothis virescens)
  305. Changes in haemolymph octopamine levels associated with food deprivation in the locust, Schistocerca gregaria
  306. Stress-induced changes in the octopamine levels of insect haemolymph
  307. Biogenic amines in the brain of the honeybee, Apis mellifera
  308. Dynamic In Vivo Imaging of Receptors in Small Animals Using Positron Emission Tomography
  309. Imaging and Characterization of Radioligands for Positron Emission Tomography Using Quantitative Phosphor Imaging Autoradiography
  310. Immunocytochemical Localization of Receptors Using Light and Confocal Microscopy With Application to the Phenotypic Characterization of Knock-Out Mice
  311. Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems
  312. Apelins and the Apelin Receptor
  313. Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors
  314. Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay